SRC mediates the activation of EGFR (for example [46]) and we found that DLD1 cells strongly activated EGFR signalling following MEK inhibitor treatment and that combined trametinib and AZD0424 treatment inhibited cell viability synergistically in vitro, but it was not sufficient to block DLD1 tumour growth in vivo implying that SRC signalling is dispensible for tumour growth in this model. The gene discussed is MAP2K7; the disease is neoplasm.